이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Safety, Pharmacokinetics, and Pharmacodynamics of Continuous KL0011034 Infusion in Healthy Chinese Adults

2026년 9월 21일 업데이트: Guoping Yang, The Third Xiangya Hospital of Central South University

A Single-Center, Randomized, Double-Blind, Active-Controlled Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Continuous Infusion of KL0011034 Injection in Healthy Chinese Adults

This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of continuous intravenous infusion of KL0011034 Injection in healthy Chinese adults. Approximately 30 participants will be enrolled in three sequential infusion-duration cohorts (1, 2, and 3 hours; 10 participants per cohort). Within each cohort, participants will be randomized in a 4:1 ratio to KL0011034 Injection or active-control propofol for anesthesia maintenance. All participants will receive propofol 2 mg/kg for anesthesia induction. Safety, pharmacokinetic, pharmacodynamic, recovery, and anesthesia-satisfaction assessments will be performed through 24 hours after dosing. Progression to the next infusion-duration cohort will occur only after the preceding cohort is considered safe and tolerable.

연구 개요

상세 설명

This is a single-center, randomized, blinded, active-controlled Phase 1 study in 30 healthy Chinese adults. The study contains three sequential cohorts defined by anesthesia-maintenance duration: 1 hour, 2 hours, and 3 hours. Each cohort will enroll approximately 10 participants. Within each cohort, participants will be randomized 4:1 to the investigational-maintenance regimen or the active-control-maintenance regimen.

All participants will receive propofol injectable emulsion 2 mg/kg intravenously over 1 minute (±5 seconds) for anesthesia induction. Maintenance infusion will begin within 30 seconds after induction. Participants assigned to the investigational regimen will receive KL0011034 Injection at a recommended maintenance rate of 1.1 mg/kg/hour; the rate may be adjusted by the investigator to maintain a bispectral index (BIS) of 40 to 60 and must not exceed the protocol-defined upper limit. Participants assigned to the active comparator will receive propofol injectable emulsion at a suggested rate of 4 to 12 mg/kg/hour, adjustable to maintain BIS at 40 to 60.

The 1-hour cohort will be evaluated before the 2-hour cohort begins, and the 2-hour cohort will be evaluated before the 3-hour cohort begins. Progression requires review confirming acceptable safety and tolerability. Participants will undergo safety monitoring, serial plasma sampling for noncompartmental pharmacokinetic analysis, and pharmacodynamic and recovery assessments including MOAA/S, BIS, Modified Aldrete Score, PADSS, recovery quality, and anesthesia satisfaction. The study includes screening, a 1-day baseline period, and approximately 24 hours of post-dose observation.

연구 유형

중재적

등록 (추정된)

30

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Participants who fully understand the purpose, content, procedures, and possible risks of the study, voluntarily agree to participate, and sign the informed consent form.
  2. Healthy male or female participants aged 18 to 45 years, inclusive, at the time of informed consent.
  3. Body weight ≥50.0 kg for males and ≥45.0 kg for females; body mass index 19.0 to 26.0 kg/m², inclusive.
  4. From informed consent through 3 months after completion of study-drug infusion, the participant and partner have no reproductive plans and the participant has no sperm or egg donation plans; the participant agrees to use at least one non-pharmacologic contraceptive method through the last pharmacokinetic sample and effective contraception through 3 months after infusion.
  5. Able to communicate well with the investigator and willing and able to comply with protocol-specified lifestyle restrictions and complete study procedures.

Exclusion Criteria:

  1. Known allergy to etomidate, propofol, or other anesthetic drugs; allergic constitution (for example, allergy to two or more drugs, foods, or pollen); tendency to rash or urticaria; history of allergic disease; or known allergy to the active ingredient or excipients of KL0011034 Injection.
  2. History of clinically significant cardiovascular, endocrine, respiratory, gastrointestinal, urinary, neurologic, hematologic, lymphatic, or psychiatric disease that remains clinically significant at screening in the investigator's judgment.
  3. History of anesthesia accident, serious anesthesia-related adverse reaction, or family history of anesthesia accident.
  4. Difficult ventilation, suspected difficult airway, or anticipated difficult tracheal intubation, including Modified Mallampati Class III-IV, congenital small mouth with macroglossia, mandibular hypoplasia, or similar findings.
  5. History of airway disease before or at screening, including bronchial asthma, chronic obstructive pulmonary disease, or sleep apnea syndrome.
  6. History of adrenocortical insufficiency, adrenal tumor, hereditary disorder of heme biosynthesis, or hereditary acute porphyria.
  7. Clinically significant abnormal findings in physical examination, vital signs, posteroanterior chest radiograph, abdominal ultrasonography, hematology, urinalysis, blood chemistry, coagulation, or infectious-disease screening; or clinically significant abnormal overall circadian pattern of cortisol and/or ACTH at screening in the investigator's judgment.
  8. Clinically significant electrocardiogram abnormality at screening, including QTcF ≥450 ms in males or ≥460 ms in females.
  9. Pregnant or breastfeeding female, or a woman of childbearing potential with a positive pregnancy test during screening.
  10. Unprotected sexual intercourse within 2 weeks before dosing.
  11. History of drug abuse or drug dependence within 1 year before screening, or positive urine drug screen at screening.
  12. History of alcohol abuse within 6 months before screening, defined as more than 14 standard units per week (1 unit = 360 mL beer, 45 mL of 40% spirits, or 150 mL wine); positive breath alcohol test; or unwillingness to abstain from alcohol and alcohol-containing products during the study.
  13. Smoking ≥5 cigarettes per day within 6 months before screening; unwillingness to stop using tobacco products during the study; or positive smoking test at screening.
  14. Habitual consumption of more than 8 cups per day (1 cup = 250 mL) of tea, coffee, or caffeine-containing beverages, or unwillingness to abstain from these beverages during the study.
  15. Consumption of grapefruit-rich foods or beverages within 48 hours before first dosing.
  16. Use of any prescription drug, over-the-counter drug, traditional Chinese medicine, health supplement, or vitamin within 14 days before screening; or use of sedative/analgesic or other anesthetic drugs within 5 days before first dosing.
  17. Participation in any clinical trial within 3 months before dosing, or still in the follow-up period of another trial.
  18. Receipt of an inactivated vaccine within 1 month before screening or a live/attenuated vaccine within 3 months before screening, or planned vaccination during the study.
  19. Blood loss, blood donation, blood transfusion, or receipt of blood products totaling more than 400 mL within 3 months before screening; or planned blood donation or surgery during the study or within 1 month after study completion.
  20. Surgery within 3 months before screening, incomplete recovery from surgery, or planned surgery during the study.
  21. Special dietary requirements incompatible with standardized meals, swallowing difficulty, habitual anorexia or dieting, or initiation of a markedly abnormal diet (for example, a restrictive or low-sodium diet) within 4 weeks before screening.
  22. Difficult venous access, inability to tolerate venipuncture, or history of fainting in response to blood or needles.
  23. Expected poor compliance or any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 다른
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cohort 1: KL0011034, 1-Hour Infusion

Participants receive propofol injectable emulsion 2 mg/kg IV for induction, followed by KL0011034 Injection at a recommended maintenance rate of 1.1 mg/kg/hour for 1 hour. The rate may be adjusted to maintain BIS 40-60 within protocol limits.

Intravenous maintenance infusion at a recommended rate of 1.1 mg/kg/hour for 1, 2, or 3 hours according to assigned cohort. The investigator may adjust the rate to maintain BIS 40-60; any upward adjustment must remain within the protocol-defined maximum rate of 2.5 mg/kg/hour.

활성 비교기: Cohort 1: Propofol, 1-Hour Infusion

Participants receive propofol injectable emulsion 2 mg/kg IV for induction, followed by propofol injectable emulsion at 4-12 mg/kg/hour for 1 hour. The rate may be adjusted to maintain BIS 40-60.

All participants receive 2 mg/kg intravenously over 1 minute (±5 seconds) for anesthesia induction. In active-comparator arms, maintenance propofol is infused at a suggested rate of 4-12 mg/kg/hour for 1, 2, or 3 hours according to assigned cohort, adjustable to maintain BIS 40-60.

실험적: Cohort 2: KL0011034, 2-Hour Infusion

Participants receive propofol injectable emulsion 2 mg/kg IV for induction, followed by KL0011034 Injection at a recommended maintenance rate of 1.1 mg/kg/hour for 2 hours. The rate may be adjusted to maintain BIS 40-60 within protocol limits.

Intravenous maintenance infusion at a recommended rate of 1.1 mg/kg/hour for 1, 2, or 3 hours according to assigned cohort. The investigator may adjust the rate to maintain BIS 40-60; any upward adjustment must remain within the protocol-defined maximum rate of 2.5 mg/kg/hour.

활성 비교기: Cohort 2: Propofol, 2-Hour Infusion

Participants receive propofol injectable emulsion 2 mg/kg IV for induction, followed by propofol injectable emulsion at 4-12 mg/kg/hour for 2 hours. The rate may be adjusted to maintain BIS 40-60.

All participants receive 2 mg/kg intravenously over 1 minute (±5 seconds) for anesthesia induction. In active-comparator arms, maintenance propofol is infused at a suggested rate of 4-12 mg/kg/hour for 1, 2, or 3 hours according to assigned cohort, adjustable to maintain BIS 40-60.

실험적: Cohort 3: KL0011034, 3-Hour Infusion

Participants receive propofol injectable emulsion 2 mg/kg IV for induction, followed by KL0011034 Injection at a recommended maintenance rate of 1.1 mg/kg/hour for 3 hours. The rate may be adjusted to maintain BIS 40-60 within protocol limits.

Intravenous maintenance infusion at a recommended rate of 1.1 mg/kg/hour for 1, 2, or 3 hours according to assigned cohort. The investigator may adjust the rate to maintain BIS 40-60; any upward adjustment must remain within the protocol-defined maximum rate of 2.5 mg/kg/hour.

활성 비교기: Cohort 3: Propofol, 3-Hour Infusion

Participants receive propofol injectable emulsion 2 mg/kg IV for induction, followed by propofol injectable emulsion at 4-12 mg/kg/hour for 3 hours. The rate may be adjusted to maintain BIS 40-60.

All participants receive 2 mg/kg intravenously over 1 minute (±5 seconds) for anesthesia induction. In active-comparator arms, maintenance propofol is infused at a suggested rate of 4-12 mg/kg/hour for 1, 2, or 3 hours according to assigned cohort, adjustable to maintain BIS 40-60.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Adverse Events and Serious Adverse Events
기간: From informed consent through Day 2 discharge/early termination; unresolved adverse events are followed as specified in the protocol.

Incidence, severity, seriousness, relationship, and outcome of adverse events and serious adverse events.

From informed consent through Day 2 discharge/early termination; unresolved adverse events are followed as specified in the protocol.
Physical Examination Findings
기간: Screening, Day -2 as applicable, Day -1, Day 2/end-of-study, and early termination.

Number of participants with clinically significant changes or abnormalities in physical examination findings.

Screening, Day -2 as applicable, Day -1, Day 2/end-of-study, and early termination.
Holter Monitoring Findings
기간: Time-matched baseline on Day -1; Day 1 from infusion start through 24 hours after infusion at protocol-specified time points (infusion start; 30 minutes, 1, 2, 3 hours after start; 2, 10, 30 minutes, 1, 4, 12, 24 hours after completion).

Clinically significant abnormalities detected by protocol-specified Holter monitoring.

Time-matched baseline on Day -1; Day 1 from infusion start through 24 hours after infusion at protocol-specified time points (infusion start; 30 minutes, 1, 2, 3 hours after start; 2, 10, 30 minutes, 1, 4, 12, 24 hours after completion).
Plasma Cortisol Concentration
기간: Screening (Day -14 to Day -2) at 07:00-08:00, 16:00 , and 00:00; time-matched baseline on Day -1; on Day 1, pre-dose, at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, and 8 hours after infusion start, and at 16:00 and 00:00; and on Day 2 at 08:00.

Plasma cortisol concentration (measured in nmol/L) assessed by protocol-specified laboratory testing.

Screening (Day -14 to Day -2) at 07:00-08:00, 16:00 , and 00:00; time-matched baseline on Day -1; on Day 1, pre-dose, at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, and 8 hours after infusion start, and at 16:00 and 00:00; and on Day 2 at 08:00.
Plasma Adrenocorticotropic Hormone Concentration
기간: Screening (Day -14 to Day -2) at 07:00-08:00, 16:00 , and 00:00; time-matched baseline on Day -1; on Day 1, pre-dose, at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, and 8 hours after infusion start, and at 16:00 and 00:00; and on Day 2 at 08:00.

Plasma adrenocorticotropic hormone (ACTH) concentration (measured in pg/mL) assessed by protocol-specified laboratory testing.

Screening (Day -14 to Day -2) at 07:00-08:00, 16:00 , and 00:00; time-matched baseline on Day -1; on Day 1, pre-dose, at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, and 8 hours after infusion start, and at 16:00 and 00:00; and on Day 2 at 08:00.
Blood Pressure
기간: Day 1: pre-dose; during infusion at 30 minutes, 1, 2, 3 hours; post-infusion at 30 minutes, 1, 2, 4, 8, 12, 24 hours; and at early termination.

Change from baseline in blood pressure (systolic and diastolic, measured in mmHg) assessed by standard vital sign measurement.

Day 1: pre-dose; during infusion at 30 minutes, 1, 2, 3 hours; post-infusion at 30 minutes, 1, 2, 4, 8, 12, 24 hours; and at early termination.
Pulse Rate
기간: Day 1: pre-dose; during infusion at 30 minutes, 1, 2, 3 hours; post-infusion at 30 minutes, 1, 2, 4, 8, 12, 24 hours; and at early termination.

Change from baseline in pulse rate (measured in beats per minute) assessed by standard vital sign measurement.

Day 1: pre-dose; during infusion at 30 minutes, 1, 2, 3 hours; post-infusion at 30 minutes, 1, 2, 4, 8, 12, 24 hours; and at early termination.
Respiratory Rate
기간: Day 1: pre-dose; during infusion at 30 minutes, 1, 2, 3 hours; post-infusion at 30 minutes, 1, 2, 4, 8, 12, 24 hours; and at early termination.

Change from baseline in respiratory rate (measured in breaths per minute) assessed by standard vital sign measurement.

Day 1: pre-dose; during infusion at 30 minutes, 1, 2, 3 hours; post-infusion at 30 minutes, 1, 2, 4, 8, 12, 24 hours; and at early termination.
Body Temperature
기간: Day 1: pre-dose; during infusion at 30 minutes, 1, 2, 3 hours; post-infusion at 30 minutes, 1, 2, 4, 8, 12, 24 hours; and at early termination.

Change from baseline in tympanic body temperature (measured in degrees Celsius) assessed by standard vital sign measurement.

Day 1: pre-dose; during infusion at 30 minutes, 1, 2, 3 hours; post-infusion at 30 minutes, 1, 2, 4, 8, 12, 24 hours; and at early termination.
Oxygen Saturation (SpO2)
기간: Day 1: pre-dose; during infusion at 30 minutes, 1, 2, 3 hours; post-infusion at 30 minutes, 1, 2, 4, 8, 12, 24 hours; and at early termination.

Change from baseline in oxygen saturation (measured as percentage of oxygen saturation) assessed by pulse oximetry.

Day 1: pre-dose; during infusion at 30 minutes, 1, 2, 3 hours; post-infusion at 30 minutes, 1, 2, 4, 8, 12, 24 hours; and at early termination.
Heart Rate
기간: Pre-dose (within 1 hour before anesthesia induction); after completion of continuous infusion at 30 minutes (±5 minutes), 2 hours (±10 minutes), 4 hours (±10 minutes), 8 hours (±15 minutes), and 24 hours (±20 minutes); and at early termination.

Change from baseline in heart rate (measured in beats per minute) assessed by 12-lead electrocardiogram.

Pre-dose (within 1 hour before anesthesia induction); after completion of continuous infusion at 30 minutes (±5 minutes), 2 hours (±10 minutes), 4 hours (±10 minutes), 8 hours (±15 minutes), and 24 hours (±20 minutes); and at early termination.
PR Interval
기간: Pre-dose (within 1 hour before anesthesia induction); after completion of continuous infusion at 30 minutes (±5 minutes), 2 hours (±10 minutes), 4 hours (±10 minutes), 8 hours (±15 minutes), and 24 hours (±20 minutes); and at early termination.

Change from baseline in PR interval (measured in milliseconds) assessed by 12-lead electrocardiogram.

Pre-dose (within 1 hour before anesthesia induction); after completion of continuous infusion at 30 minutes (±5 minutes), 2 hours (±10 minutes), 4 hours (±10 minutes), 8 hours (±15 minutes), and 24 hours (±20 minutes); and at early termination.
Change From Time-Matched Baseline in Plasma Cortisol Concentration
기간: Screening (Day -14 to Day -2) at 07:00-08:00, 16:00 , and 00:00; time-matched baseline on Day -1; on Day 1, pre-dose, at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, and 8 hours after infusion start, and at 16:00 and 00:00; and on Day 2 at 08:00.

Change from time-matched baseline in plasma cortisol concentration (measured in nmol/L) assessed by protocol-specified laboratory testing.

Screening (Day -14 to Day -2) at 07:00-08:00, 16:00 , and 00:00; time-matched baseline on Day -1; on Day 1, pre-dose, at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, and 8 hours after infusion start, and at 16:00 and 00:00; and on Day 2 at 08:00.
QRS Interval
기간: Pre-dose (within 1 hour before anesthesia induction); after completion of continuous infusion at 30 minutes (±5 minutes), 2 hours (±10 minutes), 4 hours (±10 minutes), 8 hours (±15 minutes), and 24 hours (±20 minutes); and at early termination.

Change from baseline in QRS interval (measured in milliseconds) assessed by 12-lead electrocardiogram.

Pre-dose (within 1 hour before anesthesia induction); after completion of continuous infusion at 30 minutes (±5 minutes), 2 hours (±10 minutes), 4 hours (±10 minutes), 8 hours (±15 minutes), and 24 hours (±20 minutes); and at early termination.
QT Interval
기간: Pre-dose (within 1 hour before anesthesia induction); after completion of continuous infusion at 30 minutes (±5 minutes), 2 hours (±10 minutes), 4 hours (±10 minutes), 8 hours (±15 minutes), and 24 hours (±20 minutes); and at early termination.

Change from baseline in QT interval (measured in milliseconds) assessed by 12-lead electrocardiogram.

Pre-dose (within 1 hour before anesthesia induction); after completion of continuous infusion at 30 minutes (±5 minutes), 2 hours (±10 minutes), 4 hours (±10 minutes), 8 hours (±15 minutes), and 24 hours (±20 minutes); and at early termination.
QTcF Interval
기간: Pre-dose (within 1 hour before anesthesia induction); after completion of continuous infusion at 30 minutes (±5 minutes), 2 hours (±10 minutes), 4 hours (±10 minutes), 8 hours (±15 minutes), and 24 hours (±20 minutes); and at early termination.

Change from baseline in QT interval corrected using Fridericia's formula (measured in milliseconds) assessed by 12-lead electrocardiogram.

Pre-dose (within 1 hour before anesthesia induction); after completion of continuous infusion at 30 minutes (±5 minutes), 2 hours (±10 minutes), 4 hours (±10 minutes), 8 hours (±15 minutes), and 24 hours (±20 minutes); and at early termination.
Change From Time-Matched Baseline in Plasma Adrenocorticotropic Hormone Concentration
기간: Screening (Day -14 to Day -2) at 07:00-08:00, 16:00 , and 00:00; time-matched baseline on Day -1; on Day 1, pre-dose, at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, and 8 hours after infusion start, and at 16:00 and 00:00; and on Day 2 at 08:00.

Change from time-matched baseline in plasma adrenocorticotropic hormone (ACTH) concentration (measured in pg/mL) assessed by protocol-specified laboratory testing.

Screening (Day -14 to Day -2) at 07:00-08:00, 16:00 , and 00:00; time-matched baseline on Day -1; on Day 1, pre-dose, at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, and 8 hours after infusion start, and at 16:00 and 00:00; and on Day 2 at 08:00.

2차 결과 측정

결과 측정
측정값 설명
기간
Maximum Plasma Concentration (Cmax) of KL0011034
기간: pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Maximum observed plasma concentration.

pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Time to Maximum Plasma Concentration (Tmax) of KL0011034
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Time of the first occurrence of the maximum observed plasma concentration.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Area Under the Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of KL0011034
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated using the linear-up/log-down trapezoidal method.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of KL0011034
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as AUC0-t + Clast/λz.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Area Under the Curve From Time Zero to 24 Hours (AUC0-24h) of KL0011034
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated using the linear-up/log-down trapezoidal method.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Percentage of AUC Extrapolated to Infinity (AUC%Extrap) of KL0011034
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as [(AUC0-∞ - AUC0-t)/AUC0-∞] × 100%.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Clearance (CL) of KL0011034
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as Dose/AUC0-∞, as applicable.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Volume of Distribution (Vd) of KL0011034
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as Dose/(AUC0-∞ × λz), as applicable.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Terminal Elimination Rate Constant (λz) of KL0011034
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Estimated by log-linear regression of the terminal concentration-time phase using at least three points.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Terminal Elimination Half-Life (t1/2) of KL0011034
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as ln(2)/λz.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Mean Residence Time From Time Zero to Infinity (MRT0-∞) of KL0011034
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as AUMC/AUC0-∞.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Maximum Plasma Concentration (Cmax) of KL0011034 Metabolite A644S(A)-Z7
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Maximum observed plasma concentration.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Time to Maximum Plasma Concentration (Tmax) of KL0011034 Metabolite A644S(A)-Z7
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Time of the first occurrence of the maximum observed plasma concentration.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Area Under the Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of KL0011034 Metabolite A644S(A)-Z7
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated using the linear-up/log-down trapezoidal method.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of KL0011034 Metabolite A644S(A)-Z7
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as AUC0-t + Clast/λz.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Area Under the Curve From Time Zero to 24 Hours (AUC0-24h) of KL0011034 Metabolite A644S(A)-Z7
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated using the linear-up/log-down trapezoidal method.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Percentage of AUC Extrapolated to Infinity (AUC%Extrap) of KL0011034 Metabolite A644S(A)-Z7
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as [(AUC0-∞ - AUC0-t)/AUC0-∞] × 100%.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Clearance (CL) of KL0011034 Metabolite A644S(A)-Z7
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as Dose/AUC0-∞, as applicable.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Volume of Distribution (Vd) of KL0011034 Metabolite A644S(A)-Z7
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as Dose/(AUC0-∞ × λz), as applicable.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Terminal Elimination Rate Constant (λz) of KL0011034 Metabolite A644S(A)-Z7
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Estimated by log-linear regression of the terminal concentration-time phase using at least three points.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Terminal Elimination Half-Life (t1/2) of KL0011034 Metabolite A644S(A)-Z7
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as ln(2)/λz.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Mean Residence Time From Time Zero to Infinity (MRT0-∞) of KL0011034 Metabolite A644S(A)-Z7
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as AUMC/AUC0-∞.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Maximum Plasma Concentration (Cmax) of Propofol
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Maximum observed plasma concentration.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Time to Maximum Plasma Concentration (Tmax) of Propofol
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Time of the first occurrence of the maximum observed plasma concentration.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Area Under the Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Propofol
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated using the linear-up/log-down trapezoidal method.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Propofol
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as AUC0-t + Clast/λz.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Area Under the Curve From Time Zero to 24 Hours (AUC0-24h) of Propofol
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated using the linear-up/log-down trapezoidal method.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Percentage of AUC Extrapolated to Infinity (AUC%Extrap) of Propofol
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as [(AUC0-∞ - AUC0-t)/AUC0-∞] × 100%.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Clearance (CL) of Propofol
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as Dose/AUC0-∞, as applicable.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Volume of Distribution (Vd) of Propofol
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as Dose/(AUC0-∞ × λz), as applicable.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Terminal Elimination Rate Constant (λz) of Propofol
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Estimated by log-linear regression of the terminal concentration-time phase using at least three points.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Terminal Elimination Half-Life (t1/2) of Propofol
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as ln(2)/λz.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Mean Residence Time From Time Zero to Infinity (MRT0-∞) of Propofol
기간: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

Calculated as AUMC/AUC0-∞.

Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.
Sedation/Anesthesia Success Rate
기간: Day 1, from start of anesthesia induction until MOAA/S ≤1, assessed up to 24 hours after the start of infusion.

Proportion of participants meeting the protocol-defined success criterion: MOAA/S score ≤1 after anesthesia induction.

Day 1, from start of anesthesia induction until MOAA/S ≤1, assessed up to 24 hours after the start of infusion.
Duration With Bispectral Index ≤60
기간: Day 1, continuously from pre-induction until 10 minutes after full recovery.

Duration for which BIS is 60 or lower.

Day 1, continuously from pre-induction until 10 minutes after full recovery.
Total Duration With Bispectral Index 40 to 60
기간: Day 1, continuously from pre-induction until 10 minutes after full recovery.

Cumulative duration for which BIS remains between 40 and 60.

Day 1, continuously from pre-induction until 10 minutes after full recovery.
Time to MOAA/S Score ≤1
기간: Day 1, from start of anesthesia induction until the first MOAA/S score ≤1, assessed every 20 seconds after induction up to 24 hours after the start of infusion.

Time from start of anesthesia induction to the first MOAA/S score ≤1.

Day 1, from start of anesthesia induction until the first MOAA/S score ≤1, assessed every 20 seconds after induction up to 24 hours after the start of infusion.
Total Duration With MOAA/S Score ≤1
기간: Day 1, from induction through recovery assessments, assessed up to 24 hours after the start of infusion.

Cumulative duration during which MOAA/S score is ≤1.

Day 1, from induction through recovery assessments, assessed up to 24 hours after the start of infusion.
MOAA/S Sedation Score
기간: Day 1: pre-induction; every 20 seconds after induction until MOAA/S ≤1 (assessed up to 24 hours); at 5, 10, 15, 20, 30, 45 minutes and 1, 2, 3 hours after infusion start; and every 2 minutes after infusion end until 10 minutes after full recovery.

Sedation depth assessed using the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale. The scale ranges from 0 to 5, where 5 indicates responsive to normal tone of voice and 0 indicates no response to painful stimulus; higher scores indicate a more awake state.

Day 1: pre-induction; every 20 seconds after induction until MOAA/S ≤1 (assessed up to 24 hours); at 5, 10, 15, 20, 30, 45 minutes and 1, 2, 3 hours after infusion start; and every 2 minutes after infusion end until 10 minutes after full recovery.
Modified Aldrete Score
기간: Day 1, every 2 minutes after full recovery until three consecutive scores ≥9, assessed up to 24 hours after the start of infusion.

Recovery assessed using the Modified Aldrete Score. The scale ranges from 0 to 10, where higher scores indicate better recovery; readiness to leave the recovery area requires three consecutive scores ≥9.

Day 1, every 2 minutes after full recovery until three consecutive scores ≥9, assessed up to 24 hours after the start of infusion.
Post-Anesthetic Discharge Scoring System Score
기간: Day 1, every 5 minutes after three consecutive Aldrete scores ≥9 until three consecutive PADSS scores ≥9, assessed up to 24 hours after the start of infusion.

Discharge readiness assessed using the Post-Anesthetic Discharge Scoring System (PADSS). The scale ranges from 0 to 10, where higher scores indicate better discharge readiness; readiness for discharge requires three consecutive scores ≥9.

Day 1, every 5 minutes after three consecutive Aldrete scores ≥9 until three consecutive PADSS scores ≥9, assessed up to 24 hours after the start of infusion.
Time to Full Recovery
기간: Day 1, from end of infusion until full recovery, assessed up to 24 hours after the start of infusion.

Time from end of continuous infusion to the first score of 5 in three consecutive MOAA/S scores of 5.

Day 1, from end of infusion until full recovery, assessed up to 24 hours after the start of infusion.
Time to Recovery-Area Discharge Readiness
기간: Day 1, from full recovery until recovery-area discharge criteria are met, assessed up to 24 hours after the start of infusion.

Time until three consecutive Modified Aldrete scores are ≥9.

Day 1, from full recovery until recovery-area discharge criteria are met, assessed up to 24 hours after the start of infusion.
Time to Hospital Discharge Readiness
기간: Day 1, from recovery-area discharge readiness until hospital discharge criteria are met, assessed up to 24 hours after the start of infusion.

Time until three consecutive PADSS scores are ≥9.

Day 1, from recovery-area discharge readiness until hospital discharge criteria are met, assessed up to 24 hours after the start of infusion.
Mini-Mental State Examination Score
기간: Day -1, and within 30 minutes, 1 hour, 2 hours, and 4 hours after discharge readiness; later assessments may stop once the result is normal.

Orientation and memory during recovery assessed using the Mini-Mental State Examination (MMSE). The scale ranges from 0 to 30, where higher scores indicate better cognitive function.

Day -1, and within 30 minutes, 1 hour, 2 hours, and 4 hours after discharge readiness; later assessments may stop once the result is normal.
Finger-to-Nose Test Result
기간: Day -1, and within 30 minutes, 1 hour, 2 hours, and 4 hours after discharge readiness; later assessments may stop once the result is normal.

Motor coordination during recovery assessed using the finger-to-nose test.

Day -1, and within 30 minutes, 1 hour, 2 hours, and 4 hours after discharge readiness; later assessments may stop once the result is normal.
Anesthesiologist Satisfaction
기간: 30 minutes (±10 minutes) after full recovery on Day 1.

Anesthesiologist satisfaction with anesthesia, assessed using the protocol-specified satisfaction assessment.

30 minutes (±10 minutes) after full recovery on Day 1.
Injection Site Reactions
기간: Day 1: pre-dose; 10 seconds after induction; at infusion start; 1, 2, 3 hours after start; 10 minutes after full recovery; before Day 2 discharge; and at early termination (within 6 hours after infusion end).

Incidence and severity of injection-site pain, tenderness, erythema, and induration/mass.

Day 1: pre-dose; 10 seconds after induction; at infusion start; 1, 2, 3 hours after start; 10 minutes after full recovery; before Day 2 discharge; and at early termination (within 6 hours after infusion end).

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 6일

기본 완료 (추정된)

2027년 9월 5일

연구 완료 (추정된)

2027년 9월 5일

연구 등록 날짜

최초 제출

2026년 8월 31일

QC 기준을 충족하는 최초 제출

2026년 9월 21일

처음 게시됨 (실제)

2026년 9월 25일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 25일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 21일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual participant data (IPD) will not be shared because this is a first-in-human or early-stage clinical trial involving a novel investigational drug. The data contain proprietary and confidential information that could compromise ongoing patent applications and future commercial development. Public data sharing at this stage may also violate our confidentiality agreements with the contract research organization (CRO) and regulatory authorities. Therefore, IPD sharing is not feasible until the drug receives market approval or the primary study results are fully published.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다